News

Immune Pharmaceuticals to restructure

Tuesday, April 25, 2017

Immune Pharmaceuticals, a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced a major corporate restructuring with the objective of prioritizing and segregating its R&D efforts on a focused set of products in inflammatory disease and dermatology and strengthening its financial position. 

[Read More]

HitGen partners with Scripps Research Institute and Calibr

Monday, April 24, 2017

HitGen, a privately held biotech company focused on technology for effective and efficient small molecule drug discovery and development, announced a collaboration with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr). This collaboration is to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.

[Read More]

NIH funds seven international centers of excellence for Malaria research

Monday, April 24, 2017

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, announced approximately $9 million in first-year funding, subject to availability, for seven malaria research centers around the world. The seven-year awards continue NIAID’s 2010 program that created the International Centers of Excellence for Malaria Research (ICEMRs) in regions where malaria is endemic. The awards fund three new and four existing centers that work in 14 countries in Africa, Asia and Latin America.

[Read More]

VolitionRX opens new R&D facility in Belgium

Monday, April 24, 2017

VolitionRx opened its new R&D facility. The new building will enable the company to increase capacity to carry out clinical trials and to expand its scientific team, thereby expediting the large number of trials underway. The new custom-designed facility comprises 9,000 square feet of office space and 10,000 square feet of high quality, purpose-built laboratory space. The facility is located in the Crealys Science Park, Isnes in the Wallonia region of Belgium, an area popular with other biotech and pharmaceutical companies.

[Read More]